GMAB – Genmab A/S

GMAB — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

1.44

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.23

EPS Last/This Y

-0.46

EPS This/Next Y

0.69

Price

25.85

Target Price

36.79

Analyst Recom

1.56

Performance Q

-22.71

Upside

110.0%

Beta

0.99

Ticker: GMAB

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	GMAB	27.66	0.85	5.78	11503
2026-03-04	GMAB	28.2	0.94	3.70	12210
2026-03-06	GMAB	27.05	1.03	0.41	13282
2026-03-09	GMAB	27.26	1.01	1.77	13678
2026-03-10	GMAB	27.98	1.01	0.83	13706
2026-03-11	GMAB	27.38	1.01	4.51	13708
2026-03-12	GMAB	26.59	1.04	0.75	14103
2026-03-13	GMAB	26.57	1.04	0.76	14103
2026-03-17	GMAB	26.39	0.99	0.73	15923
2026-03-18	GMAB	25.84	0.98	0.48	16584
2026-03-20	GMAB	25.12	0.89	6.41	18062
2026-03-25	GMAB	26.11	1.04	0.03	18957
2026-03-26	GMAB	26.04	1.02	3.00	19150
2026-03-27	GMAB	25.83	1.02	0.04	19154
2026-03-30	GMAB	25.84	1.00	29.83	19341
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	GMAB	29.65	-55.7	-66.4	1.02
2026-03-03	GMAB	27.67	-55.7	-142.5	1.02
2026-03-04	GMAB	28.18	-55.7	-71.4	1.02
2026-03-05	GMAB	27.47	-55.7	-111.3	1.09
2026-03-06	GMAB	27.03	-55.7	-102.0	1.09
2026-03-09	GMAB	27.25	-55.7	-75.4	1.09
2026-03-10	GMAB	27.97	-55.7	-48.0	1.09
2026-03-11	GMAB	27.37	-55.7	-101.9	1.09
2026-03-12	GMAB	26.59	-55.7	-111.1	1.09
2026-03-13	GMAB	26.13	-55.7	-133.4	1.09
2026-03-17	GMAB	26.36	-55.7	-98.1	1.09
2026-03-18	GMAB	25.84	-55.7	-115.0	1.09
2026-03-19	GMAB	25.74	-55.7	-96.4	1.09
2026-03-20	GMAB	25.10	-55.7	-81.6	1.09
2026-03-23	GMAB	25.68	-55.7	-77.2	1.09
2026-03-24	GMAB	25.81	-55.7	-42.2	1.09
2026-03-25	GMAB	26.12	-55.7	-35.0	1.09
2026-03-26	GMAB	26.05	-55.7	-51.3	1.09
2026-03-27	GMAB	25.82	-55.7	-84.3	1.09
2026-03-30	GMAB	25.85	-55.7	-68.1	1.09
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	GMAB	0	0.62	1.28
2026-03-03	GMAB	0	0.62	1.28
2026-03-04	GMAB	0	0.62	1.28
2026-03-05	GMAB	0	0.62	0
2026-03-06	GMAB	0	0.62	1.28
2026-03-09	GMAB	0	0.62	1.28
2026-03-10	GMAB	0	0.62	1.28
2026-03-11	GMAB	0	0.62	1.41
2026-03-12	GMAB	0	0.62	1.41
2026-03-13	GMAB	0	0.62	1.41
2026-03-17	GMAB	0	0.65	1.41
2026-03-18	GMAB	0	0.65	1.41
2026-03-19	GMAB	0	0.65	1.41
2026-03-20	GMAB	0	0.65	1.41
2026-03-23	GMAB	0	0.60	1.41
2026-03-24	GMAB	0	0.60	1.41
2026-03-25	GMAB	0	0.60	1.44
2026-03-26	GMAB	0	0.60	1.44
2026-03-27	GMAB	0	0.60	1.44
2026-03-30	GMAB	0	0.57	1.44
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.05

Avg. EPS Est. Current Quarter

0.14

Avg. EPS Est. Next Quarter

0.28

Insider Transactions

Institutional Transactions

0.57

Beta

0.99

Average Sales Estimate Current Quarter

5824

Average Sales Estimate Next Quarter

6834

Fair Value

29.66

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

47.3

Max Drawdown 5-Year %

-63.1

Target Price

36.79

P/E

16.69

Forward P/E

14.37

PEG

0.75

P/S

4.27

P/B

2.72

P/Free Cash Flow

13.81

EPS

1.55

Average EPS Est. Cur. Y

1.09

EPS Next Y. (Est.)

1.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

25.91

Relative Volume

0.48

Return on Equity vs Sector %

-11

Return on Equity vs Industry %

5.3

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

-0.13

EBIT Estimation

-68.1

◆ GMAB Healthcare

$25.83

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

23/25

Volume

11/15

Valuation

18/20

TP/AR

3/10

Options

2/10

RSI

35.9

Range 1M

16.7%

Sup Dist

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

2/25

Growth

12/30

Estimates

8/20

Inst/Vol

4/15

Options

3/10

EPS Yr

-20%

EPS NY

46.3%

52W%

46.9%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +84.2% upside

Quality

17/30

Valuation

24/30

Growth

10/25

Stability

5/10

LT Trend

3/5

Upside

+84.2%

Quality

MoS

15%

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 2973

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

GMAB

Latest News

—

Caricamento notizie per GMAB…

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

NVO — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

0.73

Margin Of Safety %

Put/Call OI Ratio

0.8

EPS Next Q Diff

4.02

EPS Last/This Y

17.69

EPS This/Next Y

0.65

Price

35.31

Target Price

47.71

Analyst Recom

2.56

Performance Q

-32.65

Upside

27.8%

Beta

0.74

Ticker: NVO

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-03	NVO	36.66	0.72	0.77	1568494
2026-03-04	NVO	38.45	0.72	0.50	1617740
2026-03-06	NVO	38.6	0.72	0.47	1684708
2026-03-09	NVO	39.82	0.73	0.25	1621827
2026-03-10	NVO	38.72	0.72	0.36	1637122
2026-03-11	NVO	38.85	0.72	0.46	1662327
2026-03-12	NVO	38.03	0.72	1.44	1677403
2026-03-13	NVO	38.02	0.72	1.92	1677403
2026-03-17	NVO	38.44	0.72	0.60	1666581
2026-03-18	NVO	37.47	0.72	0.63	1676885
2026-03-20	NVO	36.49	0.71	0.68	1717087
2026-03-25	NVO	36.35	0.76	1.60	1521307
2026-03-26	NVO	36.4	0.78	0.42	1548195
2026-03-27	NVO	36.07	0.77	0.59	1594485
2026-03-30	NVO	35.31	0.80	0.40	1547432
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	NVO	37.75	-24.4	-1627.7	21.05
2026-03-03	NVO	36.70	-24.4	-2372.3	21.05
2026-03-04	NVO	38.44	-24.4	-1105.7	21.05
2026-03-05	NVO	39.06	0.6	-1871.2	21.05
2026-03-06	NVO	38.58	0.6	-2339.9	21.05
2026-03-09	NVO	39.81	0.6	-1903.2	21.05
2026-03-10	NVO	38.75	0.6	-2728.2	21.05
2026-03-11	NVO	38.85	0.6	-2164.7	21.05
2026-03-12	NVO	38.03	0.6	-2729.5	21.05
2026-03-13	NVO	37.98	0.6	-2535.4	21.05
2026-03-17	NVO	38.44	0.6	-2361.5	21.05
2026-03-18	NVO	37.49	0.6	-3113.7	21.05
2026-03-19	NVO	37.07	0.6	-2780.1	21.05
2026-03-20	NVO	36.53	0.6	-2774.0	21.05
2026-03-23	NVO	36.83	0.6	-2601.1	21.05
2026-03-24	NVO	36.89	0.6	-2575.7	21.21
2026-03-25	NVO	36.34	0.6	-2696.7	21.21
2026-03-26	NVO	36.38	0.6	-2479.4	21.21
2026-03-27	NVO	36.03	0.6	-2834.9	21.21
2026-03-30	NVO	35.31	3.3	-1822.9	21.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	NVO	0.00	-0.41	0.80
2026-03-03	NVO	0.00	-0.41	0.80
2026-03-04	NVO	0.00	-0.41	0.80
2026-03-05	NVO	0.00	-0.41	0.80
2026-03-06	NVO	0.00	-0.41	0.80
2026-03-09	NVO	0.00	-0.40	0.80
2026-03-10	NVO	0.00	-0.40	0.80
2026-03-11	NVO	0.00	-0.40	0.84
2026-03-12	NVO	0.00	-0.40	0.84
2026-03-13	NVO	0.00	-0.40	0.84
2026-03-17	NVO	0.00	-0.32	0.84
2026-03-18	NVO	0.00	-0.32	0.84
2026-03-19	NVO	0.00	-0.32	0.84
2026-03-20	NVO	0.00	-0.32	0.84
2026-03-23	NVO	0.00	0.03	0.84
2026-03-24	NVO	0.00	0.03	0.84
2026-03-25	NVO	0.00	0.03	0.73
2026-03-26	NVO	0.00	0.03	0.73
2026-03-27	NVO	0.00	0.03	0.73
2026-03-30	NVO	0.00	0.30	0.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

6.74

Avg. EPS Est. Next Quarter

5.02

Insider Transactions

Institutional Transactions

0.3

Beta

0.74

Average Sales Estimate Current Quarter

74849

Average Sales Estimate Next Quarter

71393

Fair Value

44.3

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

76.2

Max Drawdown 5-Year %

-75.3

Target Price

47.71

P/E

10.18

Forward P/E

10.62

PEG

P/S

2.54

P/B

5.14

P/Free Cash Flow

13.28

EPS

3.47

Average EPS Est. Cur. Y

21.34

EPS Next Y. (Est.)

21.98

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

33.03

Relative Volume

0.73

Return on Equity vs Sector %

25.3

Return on Equity vs Industry %

16.1

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.29

EBIT Estimation

-1822.9

◆ NVO Healthcare

$35.29

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

7/25

Volume

9/15

Valuation

18/20

TP/AR

0/10

Options

3/10

RSI

Range 1M

1.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

8/30

Estimates

6/20

Inst/Vol

2/15

Options

7/10

EPS Yr

-11.4%

EPS NY

3.1%

52W%

0.1%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +369.5% upside

Quality

30/30

Valuation

24/30

Growth

8/25

Stability

4/10

LT Trend

4/5

Upside

+369.5%

Quality

MoS

25%

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 68794

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NVO

Latest News

—

Caricamento notizie per NVO…

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

ASND — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

6.33

Margin Of Safety %

-21

Put/Call OI Ratio

0.14

EPS Next Q Diff

1.6

EPS Last/This Y

8.99

EPS This/Next Y

6.58

Price

218.19

Target Price

284.05

Analyst Recom

1.22

Performance Q

4.48

Upside

-167.3%

Beta

0.51

Ticker: ASND

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	ASND	242.34	0.27	0.17	14784
2026-03-03	ASND	240.22	0.26	0.39	14663
2026-03-04	ASND	241.71	0.26	0.18	14820
2026-03-05	ASND	237.58	0.27	0.48	14861
2026-03-06	ASND	241	0.25	0.17	15062
2026-03-09	ASND	240.1	0.24	0.05	16525
2026-03-10	ASND	240.54	0.23	0.01	17274
2026-03-11	ASND	227.29	0.23	0.14	17458
2026-03-12	ASND	229.01	0.18	0.21	20522
2026-03-13	ASND	229.01	0.18	0.21	20522
2026-03-17	ASND	228.29	0.17	0.03	20922
2026-03-18	ASND	227.53	0.17	0.76	20966
2026-03-19	ASND	223.64	0.17	1.42	20988
2026-03-20	ASND	221.94	0.17	0.15	20966
2026-03-23	ASND	218.07	0.14	0.05	16455
2026-03-24	ASND	215.6	0.14	0.03	16775
2026-03-25	ASND	220.9	0.13	0.69	17019
2026-03-26	ASND	220.43	0.14	0.17	17077
2026-03-27	ASND	216.97	0.13	0.23	17043
2026-03-30	ASND	218.19	0.14	0.44	17125
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	ASND	242.03	131.7	398.7	4.65
2026-03-03	ASND	239.06	131.7	395.8	4.65
2026-03-04	ASND	241.48	131.7	398.1	4.65
2026-03-05	ASND	237.34	131.3	394.1	4.53
2026-03-06	ASND	240.70	131.3	401.5	4.53
2026-03-09	ASND	239.96	129.6	396.1	4.52
2026-03-10	ASND	240.72	128.1	396.8	4.52
2026-03-11	ASND	227.54	128.1	383.9	4.52
2026-03-12	ASND	228.79	128.1	385.1	4.52
2026-03-13	ASND	226.03	128.1	382.4	4.52
2026-03-17	ASND	228.30	128.1	384.6	4.52
2026-03-18	ASND	227.50	128.2	383.8	4.56
2026-03-19	ASND	223.72	128.2	380.1	4.56
2026-03-20	ASND	221.88	128.2	378.3	4.56
2026-03-23	ASND	218.26	128.2	374.8	4.56
2026-03-24	ASND	215.68	128.2	372.2	4.56
2026-03-25	ASND	220.63	128.2	377.1	4.56
2026-03-26	ASND	220.61	128.2	377.1	4.56
2026-03-27	ASND	217.16	128.2	373.7	4.56
2026-03-30	ASND	218.19	128.2	374.7	4.56
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	ASND	0.00	1.40	6.25
2026-03-03	ASND	0.00	1.40	6.25
2026-03-04	ASND	0.00	1.40	6.25
2026-03-05	ASND	0.00	1.40	6.25
2026-03-06	ASND	0.00	1.40	6.25
2026-03-09	ASND	0.00	1.41	6.25
2026-03-10	ASND	0.00	1.41	6.25
2026-03-11	ASND	0.00	1.41	6.36
2026-03-12	ASND	0.00	1.41	6.36
2026-03-13	ASND	0.00	1.41	6.36
2026-03-17	ASND	0.00	1.42	6.36
2026-03-18	ASND	0.00	1.42	6.36
2026-03-19	ASND	0.00	1.42	6.36
2026-03-20	ASND	0.00	1.42	6.36
2026-03-23	ASND	0.00	1.42	6.36
2026-03-24	ASND	0.00	1.42	6.36
2026-03-25	ASND	0.00	1.42	6.33
2026-03-26	ASND	0.00	1.42	6.33
2026-03-27	ASND	0.00	1.42	6.33
2026-03-30	ASND	0.00	1.42	6.33
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.64

Avg. EPS Est. Current Quarter

0.45

Avg. EPS Est. Next Quarter

0.96

Insider Transactions

Institutional Transactions

1.42

Beta

0.51

Average Sales Estimate Current Quarter

282

Average Sales Estimate Next Quarter

327

Fair Value

171.51

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

12.2

Max Drawdown 5-Year %

-60.5

Target Price

284.05

P/E

Forward P/E

17.9

PEG

P/S

16.28

P/B

P/Free Cash Flow

260.49

EPS

-4.2

Average EPS Est. Cur. Y

4.56

EPS Next Y. (Est.)

11.13

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-30.85

Relative Volume

0.43

Return on Equity vs Sector %

112.6

Return on Equity vs Industry %

128.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.16

EBIT Estimation

374.7

◆ ASND Healthcare

$218.35

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

25/25

Volume

11/15

Valuation

12/20

TP/AR

4/10

Options

7/10

RSI

42.1

Range 1M

13.4%

Sup Dist

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

23/30

Estimates

3/20

Inst/Vol

5/15

Options

10/10

EPS Yr

212.9%

EPS NY

150.2%

52W%

75%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +38.8% upside

Quality

8/30

Valuation

11/30

Growth

17/25

Stability

6/10

LT Trend

0/5

Upside

+38.8%

Quality

MoS

-21%

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1189

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

ASND

Latest News

—

Caricamento notizie per ASND…

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y